Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
Reva Schneider1, Ayman Barakat1, John Pippen1,2,3, Cynthia Osborne1,2,3 1Medical Oncology, Baylor-Sammons Cancer Center, 2Texas Oncology PA, 3US Oncology, Dallas, TX, USA Abstract: Estrogen and its metabolites play a significant role in the proliferation of hormone receptor-positive breast cancer. I...
Guardado en:
Autores principales: | Schneider RE, Barakat AY, Pippen JE, Osborne CR |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b517bf99f4fc4d218a09d68e37c7adb0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
por: Bauer M, et al.
Publicado: (2012) -
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
por: Mo QG, et al.
Publicado: (2016) -
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations
por: Neil M. Iyengar, et al.
Publicado: (2021) -
Physical Therapies for Psychosomatic Symptoms and Quality of Life Induced by Aromatase Inhibitors in Breast Cancer Patients: A Systematic Review and Meta-Analysis
por: Xue-Ying Zhu, et al.
Publicado: (2021) -
Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani D, et al.
Publicado: (2021)